Acute Inflammation/Critical Illness Anemia

Acute Inflammation/Critical Illness Anemia is a topic covered in the Pocket ICU Management.

To view the entire topic, please or purchase a subscription.

Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drug, procedures and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and MEDLINE Journals. Explore these free sample topics:

Anesthesia Central

-- The first section of this topic is shown below --

First Things First

  • Essentially an anemia of acute, pro-inflammatory illness not related to hemorrhage, but associated with infection/inflammation
  • Distinguishing the anemia of acute inflammation in critical illness (AAICI) from iron deficiency anemia (IDA) can be difficult because of the resultant physiology of iron metabolism in illness.
    • They often coincide.
    • Pts who present with IDA as the diagnosis by default have lost physiologic reserve and have decompensated. This decompensation leads to a mixed picture of anemia and to the complexity of a straightforward diagnosis or prognosis.
  • The human body attempts to protect itself by sequestering substrates from pathogenic organisms.
  • The illness itself can cause low-level hemolysis, DIC.
  • Try to tease out the difference so that underlying disease states do not remain elusive, ultimately worsening outcome.
  • Rule out acute blood loss anemia, which may not be associated with a low-iron state initially.
  • Key features are anemia similar to chronic illness and IDA combined, with elevated fibrinogen levels, low to low-normal iron, high ferritin, low TIBC.
  • Hepcidin and pro-inflammatory cytokine related (macrophage, IL-1, IL-6)
  • Sepsis and other inflammatory disorders induce TNF-α, which stimulates macrophages responsible for IL-6.
  • IL-6 induces production of hepcidin, an iron-regulatory hormone responsible for the aspects of this disorder:
    • Inflammation leads to macrophage elaboration of IL-6, which acts on hepatocytes to induce hepcidin production.
    • Hepcidin inhibits macrophage iron release and intestinal iron absorption.
    • Inadequate RBC production secondary to poor substrate metabolism, poor iron delivery to marrow, and utilization
    • Reduced erythropoietin and RBC life span
  • Look for occult sources of blood loss (see Anemia).
  • Patients who have IDA usually have a continuous occult bleed, malignancy or myeloaffective disorder rendering them more susceptible to illness.
  • Blood loss, SIRS/sepsis, and medications are the most common cause of AAICI.
  • Hemolysis, as a component of blood loss and inflammation, often accompanies both.
    • Doesn’t have to be blood loss itself—anything that reduces blood counts, increases demands or affects iron metabolism can lead to IDA, AAICI or both.
  • Iron-deficient RBC production is evident in up to 35% of critically ill patients at admission.
  • Prolongs LOS in ICU, but treatment options often cause risks that increase LOS
  • Dramatic reticulocytosis—often in the 20% range in IDA, less so in AAICI
  • Blood loss can also be iatrogenic in combination with low-level hemolysis, DIC and reduced RBC life span in the ICU.

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: May 5, 2010